Hemab Therapeutics (NASDAQ:COAG) Posts Quarterly Earnings Results, Misses Estimates By $0.17 EPS

Hemab Therapeutics (NASDAQ:COAG) issued its earnings results on Tuesday. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.17), FiscalAI reports.

Hemab Therapeutics Price Performance

Shares of NASDAQ COAG opened at $51.74 on Wednesday. The stock has a market cap of $2.42 billion and a PE ratio of -2.16. Hemab Therapeutics has a 12-month low of $23.00 and a 12-month high of $53.61. The firm’s 50-day simple moving average is $37.46.

Wall Street Analysts Forecast Growth

COAG has been the subject of a number of research reports. Wall Street Zen upgraded Hemab Therapeutics to a “hold” rating in a research report on Saturday, May 9th. Wedbush reaffirmed an “outperform” rating and set a $55.00 price target (up from $42.00) on shares of Hemab Therapeutics in a research report on Monday, July 13th. Jefferies Financial Group raised their price objective on shares of Hemab Therapeutics from $39.00 to $47.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Evercore initiated coverage on shares of Hemab Therapeutics in a report on Tuesday, May 26th. They set an “outperform” rating and a $50.00 target price for the company. Finally, HC Wainwright lifted their price target on shares of Hemab Therapeutics from $52.00 to $60.00 and gave the stock a “buy” rating in a research note on Tuesday. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, Hemab Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $49.60.

Insider Activity

In other news, major shareholder Ra Capital Management, L.P. bought 61,523 shares of the firm’s stock in a transaction on Tuesday, June 16th. The stock was acquired at an average cost of $24.98 per share, with a total value of $1,536,844.54. Following the transaction, the insider directly owned 6,444,637 shares in the company, valued at approximately $160,987,032.26. This trade represents a 0.96% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders purchased a total of 72,467 shares of company stock valued at $1,809,595 in the last ninety days.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.